| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -43,578 | -29,621 |
| Stock-based compensation expense | 16,992 | 11,826 |
| Impairment of capitalized software development costs | 0 | 0 |
| Change in allowance for credit losses | 0 | 0 |
| Inventory write-down (recovery), net | -24 | -96 |
| Depreciation and amortization expense | 823 | 577 |
| Amortization of debt discount and debt issuance costs | 38 | 24 |
| Net accretion of discounts on marketable securities | 379 | 339 |
| Non-cash lease expense | 1,080 | 615 |
| Accounts receivable | 531 | 1,941 |
| Inventory | -45 | -1,066 |
| Prepaid expenses and other current assets | -186 | -1,099 |
| Other assets | 237 | 359 |
| Accounts payable | 2,766 | 2,645 |
| Accrued liabilities | -1,836 | -2,364 |
| Income taxes payable | 85 | 92 |
| Lease liabilities | -674 | -293 |
| Deferred revenue | -48 | -61 |
| Net cash used in operating activities | -25,292 | -17,130 |
| Purchases of investments | 5,651 | 5,651 |
| Maturities of investments | 36,585 | 27,785 |
| Purchases of property and equipment and internal software development costs | 439 | 350 |
| Net cash provided by investing activities | 30,495 | 21,784 |
| Repayment of credit agreement | 49 | 48 |
| Debt issuance cost | 70 | 47 |
| Proceeds from exercise of common stock options | 143 | 138 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 754 | 554 |
| Net cash provided by financing activities | 778 | 597 |
| Effect of exchange rate changes on cash and cash equivalents | -333 | -688 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 5,648 | 4,563 |
| Cash and cash equivalents at beginning of period | 71,162 | - |
| Cash and cash equivalents at end of period | 76,810 | - |
Pulmonx Corp (LUNG)
Pulmonx Corp (LUNG)